Analyst Research

Report Title Price
Provider: MarketLine (a Datamonitor Company)
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ipsen SA to Acquire Syntaxin Ltd

Monday, 15 Jul 2013 01:00am EDT 

Ipsen SA announced that it has signed an agreement to acquire a United Kingdom-based company Syntaxin Ltd. Under the terms of the agreement, Ipsen SA will pay EUR 28 million upfront, as well as further contingent payments that could reach EUR 130 million or more depending on the achievement of development and commercial milestones. Furthermore, Syntaxin SA’s shareholders will receive the greater part of additional downstream payments related to the company’s advanced asset, currently in Phase II clinical trials. Syntaxin Ltd has a experience in botulinum toxin biology, supported by a patent portfolio – with 75 granted patents and over 130 patents pending. 

Company Quote

-0.3 -0.94%
11:37am EDT